Gut bacterial alpha-glucosidase

Gut bacterial alpha-glucosidases are a diverse group of enzymes produced by the intestinal microbiota, notably members of the Firmicutes phylum such as Blautia obeum (formerly Ruminococcus obeum), that catalyze the hydrolysis of terminal, non-reducing alpha-1,4-linked glucose residues from oligosaccharides and disaccharides (Tan et al., 2010). These enzymes are structural and functional homologs of human intestinal alpha-glucosidases and are members of the glycoside hydrolase family 31 (GH31) (Tan et al., 2010). While traditionally viewed as off-targets for antidiabetic drugs like acarbose, they are increasingly recognized as therapeutic targets due to their role in modulating the gut environment (Zhang et al., 2020). Inhibition of these bacterial enzymes prevents the rapid conversion of dietary carbohydrates into glucose, allowing undigested sugars to reach the distal colon where they are fermented into beneficial short-chain fatty acids (SCFAs) like butyrate (Zhang et al., 2020). This shift in metabolic activity not only aids in glycemic control but also exerts systemic anti-inflammatory effects, showing promise in treating conditions such as rheumatoid arthritis and obesity (Zhang et al., 2020). However, the fermentation of these undigested carbohydrates by other colonic bacteria is the primary cause of the gastrointestinal side effects, such as flatulence and bloating, which limit the clinical utility of non-selective inhibitors (StatPearls, 2024).

Other names

Bacterial alpha-glucosidaseGut microbial alpha-glucosidaseGH31 family alpha-glucosidaseMicrobial alpha-glucosidaseRo-alphaG1

Competitive and reversible inhibition of alpha-glucosidase enzymes in the gut, which delays the hydrolysis of oligosaccharides and disaccharides into absorbable monosaccharides, thereby reducing postprandial blood glucose spikes and shifting carbohydrate fermentation to the colon to produce short-chain fatty acids (StatPearls, 2024; Zhang et al., 2020).